{
    "info": {
        "nct_id": "NCT03112694",
        "official_title": "A Multicenter, Retrospective, Medical Record Review Of The Effectiveness Of Lanreotide Following Treatment With Octreotide In Patients With Neuroendocrine Tumors",
        "inclusion_criteria": "* Males and females age 18 years or older at time of locally advanced or metastatic diagnosis\n* Patients with a confirmed diagnosis of locally advanced or metastatic Gastroenteropancreatic neuroendocrine tumour (GEP-NET)\n* Patients who switched treatment from long acting octreotide LAR to lanreotide, where both treatments were received for the treatment of locally advanced or metastatic GEP-NET. i. Treatment with long acting octreotide LAR monotherapy for at least 90-days before treatment with lanreotide monotherapy (rescue SSA# use permitted). ii. Treatment with lanreotide monotherapy for at least 90-days after treatment with long acting octreotide monotherapy (rescue SSA# use permitted)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients with other malignant disease\n* Patients who participated in a concomitant clinical trial related to treatment of GEP-NET\n* Patients being treated with a Somatostatin analogue (SSA) in combination with other NET treatments excluding rescue SSA#\n* Patients who received other primary treatment (e.g., targeted therapy, chemotherapy) for GEP-NET during the interval between octreotide and lanreotide\n* Patients with NET familial genetic syndrome (i.e., MEN1)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Males and females age 18 years or older at time of locally advanced or metastatic diagnosis",
            "criterions": [
                {
                    "exact_snippets": "Males and females",
                    "criterion": "gender",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "age 18 years or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic diagnosis",
                    "criterion": "diagnosis stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a confirmed diagnosis of locally advanced or metastatic Gastroenteropancreatic neuroendocrine tumour (GEP-NET)",
            "criterions": [
                {
                    "exact_snippets": "confirmed diagnosis of locally advanced or metastatic Gastroenteropancreatic neuroendocrine tumour (GEP-NET)",
                    "criterion": "Gastroenteropancreatic neuroendocrine tumour (GEP-NET)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "confirmed"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who switched treatment from long acting octreotide LAR to lanreotide, where both treatments were received for the treatment of locally advanced or metastatic GEP-NET. i. Treatment with long acting octreotide LAR monotherapy for at least 90-days before treatment with lanreotide monotherapy (rescue SSA# use permitted). ii. Treatment with lanreotide monotherapy for at least 90-days after treatment with long acting octreotide monotherapy (rescue SSA# use permitted)",
            "criterions": [
                {
                    "exact_snippets": "Patients who switched treatment from long acting octreotide LAR to lanreotide",
                    "criterion": "treatment switch",
                    "requirements": [
                        {
                            "requirement_type": "from",
                            "expected_value": "long acting octreotide LAR"
                        },
                        {
                            "requirement_type": "to",
                            "expected_value": "lanreotide"
                        }
                    ]
                },
                {
                    "exact_snippets": "both treatments were received for the treatment of locally advanced or metastatic GEP-NET",
                    "criterion": "treatment purpose",
                    "requirements": [
                        {
                            "requirement_type": "condition",
                            "expected_value": [
                                "locally advanced GEP-NET",
                                "metastatic GEP-NET"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with long acting octreotide LAR monotherapy for at least 90-days before treatment with lanreotide monotherapy",
                    "criterion": "treatment duration",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": "long acting octreotide LAR monotherapy"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "sequence",
                            "expected_value": "before treatment with lanreotide monotherapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with lanreotide monotherapy for at least 90-days after treatment with long acting octreotide monotherapy",
                    "criterion": "treatment duration",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": "lanreotide monotherapy"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "sequence",
                            "expected_value": "after treatment with long acting octreotide monotherapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "volunteer health status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "healthy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients with other malignant disease",
            "criterions": [
                {
                    "exact_snippets": "Patients with other malignant disease",
                    "criterion": "other malignant disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who participated in a concomitant clinical trial related to treatment of GEP-NET",
            "criterions": [
                {
                    "exact_snippets": "Patients who participated in a concomitant clinical trial",
                    "criterion": "participation in a concomitant clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "related to",
                            "expected_value": "treatment of GEP-NET"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients being treated with a Somatostatin analogue (SSA) in combination with other NET treatments excluding rescue SSA#",
            "criterions": [
                {
                    "exact_snippets": "Patients being treated with a Somatostatin analogue (SSA)",
                    "criterion": "Somatostatin analogue (SSA) treatment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in combination with other NET treatments",
                    "criterion": "NET treatments",
                    "requirements": [
                        {
                            "requirement_type": "combination with SSA",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "excluding rescue SSA",
                    "criterion": "rescue SSA",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who received other primary treatment (e.g., targeted therapy, chemotherapy) for GEP-NET during the interval between octreotide and lanreotide",
            "criterions": [
                {
                    "exact_snippets": "Patients who received other primary treatment (e.g., targeted therapy, chemotherapy) for GEP-NET",
                    "criterion": "primary treatment for GEP-NET",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "during the interval between octreotide and lanreotide",
                    "criterion": "treatment interval",
                    "requirements": [
                        {
                            "requirement_type": "specific interval",
                            "expected_value": "between octreotide and lanreotide"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with NET familial genetic syndrome (i.e., MEN1)",
            "criterions": [
                {
                    "exact_snippets": "NET familial genetic syndrome (i.e., MEN1)",
                    "criterion": "NET familial genetic syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "MEN1",
                    "criterion": "MEN1",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}